The article discusses Amgen Inc.’s patent estate that allowed them access to F. Hoffman – La Roche’s cell lines for their European product, Mircera.  Iwanicki comments that Amgen’s motivation for seeking the cell lines is to simply find out how the drug operates in the human body.  If allowed into the U.S., Mircera would be a competitor for Amgen’s product, Aranesp.

Please click here to view the article.